Acacia Drug Patent Portfolio
Acacia owns 1 orange book drug protected by 11 US patents Given below is the list of Acacia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9827251 | Dosing regimen for sedation with CNS 7056 (remimazolam) | 13 Jan, 2034 | Active |
| US9561236 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | 30 Apr, 2033 | Active |
| US10052334 | Dosing regimen for sedation with CNS 7056 (remimazolam) | 07 Nov, 2031 | Active |
| US10195210 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | 07 Nov, 2031 | Active |
| US10342800 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | 07 Nov, 2031 | Active |
| US10722522 | Dosing regimen for sedation with CNS 7056 (remimazolam) | 07 Nov, 2031 | Active |
| US9737547 | Dosing regimen for sedation with CNS 7056 (Remimazolam) | 07 Nov, 2031 | Active |
| US10472365 | Short-acting benzodiazepine salts and their polymorphic forms | 10 Jul, 2027 | Active |
| US10961250 | Short-acting benzodiazepine salts and their polymorphic forms | 10 Jul, 2027 | Active |
| US9777007 | Short-acting benzodiazepine salts and their polymorphic forms | 10 Jul, 2027 | Active |
| US9914738 | Short-acting benzodiazepine salts and their polymorphic forms | 10 Jul, 2027 | Active |
Latest Legal Activities on Acacia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Acacia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Sep, 2025 | US9914738 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 May, 2025 | US9827251 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Apr, 2025 | US9777007 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Feb, 2025 | US9737547 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Sep, 2024 | US10961250 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 07 Aug, 2024 | US9561236 |
|
Patent Term Extension Certificate
Critical
| 21 May, 2024 | US9827251 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Jan, 2024 | US10722522 |
| Notice of Final Determination -Eligible | 20 Dec, 2023 | US9827251 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Dec, 2023 | US9777007 |
|
Email Notification
Critical
| 19 Dec, 2023 | US9777007 |
|
Email Notification
Critical
| 18 Dec, 2023 | US10472365 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Dec, 2023 | US10961250 |
|
Email Notification
Critical
| 18 Dec, 2023 | US9914738 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Dec, 2023 | US9914738 |
Acacia's Family Patents
Acacia drugs have patent protection in a total of 24 countries. It's US patent count contributes only to 24.2% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Acacia Drug List
Given below is the complete list of Acacia's drugs and the patents protecting them.
1. Byfavo
Byfavo is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9827251 | Dosing regimen for sedation with CNS 7056 (remimazolam) |
13 Jan, 2034
(7 years from now)
| Active |
| US9561236 | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
30 Apr, 2033
(6 years from now)
| Active |
| US10052334 | Dosing regimen for sedation with CNS 7056 (remimazolam) |
07 Nov, 2031
(5 years from now)
| Active |
| US10195210 | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
07 Nov, 2031
(5 years from now)
| Active |
| US10342800 | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
07 Nov, 2031
(5 years from now)
| Active |
| US10722522 | Dosing regimen for sedation with CNS 7056 (remimazolam) |
07 Nov, 2031
(5 years from now)
| Active |
| US9737547 | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
07 Nov, 2031
(5 years from now)
| Active |
| US10472365 | Short-acting benzodiazepine salts and their polymorphic forms |
10 Jul, 2027
(11 months from now)
| Active |
| US10961250 | Short-acting benzodiazepine salts and their polymorphic forms |
10 Jul, 2027
(11 months from now)
| Active |
| US9777007 | Short-acting benzodiazepine salts and their polymorphic forms |
10 Jul, 2027
(11 months from now)
| Active |
| US9914738 | Short-acting benzodiazepine salts and their polymorphic forms |
10 Jul, 2027
(11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Byfavo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List